You are here

Anti-Androgen Receptor MAbs for Human Prostate Cancer

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 21968
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1993
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
11555 Sorrento Valley Road
San Diego, CA 92121
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Chiu-yang Shih
 (619) 792-5730
Business Contact
Phone: () -
Research Institution
N/A
Abstract

Each year more than one hundred thousand cases of prostate cancer have been diagnosed in the United States. Prostate cancer is the first in solid tumor incidence and second in cancer related death in the American male population. Yet, the factors which are involved in prostate carcinogenesis, except for the presence of androgen, remain unclear. It has been shown that metastatic prostate cancer patients with higher pretreatment plasma testosterone levels tend to have a greater survival rate when receiving primary hormonal therapy than those patients with low testosterone levels at the time of diagnosis. Thus, the androgen and androgen receptor (AR) expression may play an important role during prostate carcinogenesis. Recently, the anti-AR monoclonal antibody (mAb) has become available which make the assessment of AR levels and their localization in tissues possible. These anti-AR mAbs were developed using peptide fragments as immunogens, and they do not always stain tissue effectively or inhibit AR function. Thus, the application of these mAbs has been limited. In addition, the lack of high affinity anti-AR mAbs and purified human AR proteins has hampered the development of a convenient ELISA test for clinical applications. We will focus on the production and purification of full-length AR proteins from insect cells infected with baculovirus vector carrying the AR gene; these proteins will be used as immunogens to produce high affinity anti-AR mAbs and develop immunoassays for the clinical applications in prostate cancer.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government